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 Abstract
The human placenta, characterized by the processes of passive transport and facilitated diffusion, contains nume-
rous active transport proteins, usually located in the microvilli of the syncytiotrophoblast or in the endothelium of 
the capillaries of the villi. These proteins use either the energy from ATP hydrolysis or other mechanisms resulting, 
among others, from the formation of the maternofetal ion gradient, which facilitates the transfer of various endoge-
nous substances or xenobiotics across the body membranes. The proteins either trigger the efflux of these sub-
stances from the fetal tissues via the placenta into the maternal bloodstream, or conversely, they accumulate them 
in the fetal tissues. Both the placenta and the fetus are equipped with independent systems of enzymes of 1st and 
2nd phase of substrate metabolism, such as CYP450, glucuronyltransferase or sulphatase. 
An active therapy with a wide range of drugs, often at high toxicity levels, either shortly before or during pregnancy, 
has naturally posed a question concerning the degree of impermeability of the placental barrier and how effectively 
it can be crossed, including any possible negative embryotoxic or teratogenic consequences. Such hazards seem 
to be quite real, as many drugs are substrates for ABC transporters. Also the placenta itself, including its structure, 
is subject to vast transformations during pregnancy, which may be observed as the thinning of the barrier separating 
the maternal blood from the fetal one, from 20-30μm in the first trimester of gestation down to 2-4μm in the third 
trimester of gestation.
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 Streszczenie
W łożysku ludzi oprócz transportu biernego oraz dyfuzji ułatwionej zawartych jest wiele aktywnych białek transpor-
towych zazwyczaj zlokalizowanych w mikrokosmkach syncytiotrofoblastu lub w śródbłonkach naczyń włosowatych 
kosmków. Wykorzystują energię z rozpadu ATP lub inne mechanizmy wynikające między innymi z formułującego 
się gradientu jonów pomiędzy płodem i matką sprzyjają przenikaniu przez błony różnorodnych substancji endogen-
nych lub ksenobiotyków. Kreuja albo ich wyrzut z tkanek płodu przez łożysko do krwi matki lub wręcz przeciwnie 
kumulują je w jego tkankach. Samo łożysko i płód dysponuje samodzielnymi układami enzymatycznymi pierwszej 
i drugiej fazy przemian substratów takimi jak: CYP450, glukuronylotransferazy czy sulafatazy. 
Aktywne postępowanie terapeutyczne z wykorzystaniem szerokiej gamy leków niejednokrotnie o wysokim poziomie 
toksyczności w okresie przed ciążowym oraz w ciąży rodzi pytanie na ile bariera łożyskowa jest szczelna oraz na 
ile jest skutecznie pokonywana z możliwymi negatywnymi konsekwencjami o charakterze embriotoksycznym lub 
teratogennym. Groźba wydaje się być całkowicie realna, bowiem wiele leków to substraty dla transporterów ABC. 
Również samo łożysko i jego struktura ulega w trakcie ciąży głębokim przewartościowaniom czego miarą może być 
redukcja dzielącej barierę krew matki od krwi płodu z 20-30μm w pierwszym trymestrze ciąży do 2-4μm w trzecim 
trymestrze ciąży. 
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    / ciąża / syncytiotrofoblast
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Introduction
Over	the	last	several	decades,	the	consumption	of	medicines	
either	 shortly	before	or	 during	pregnancy	has	been	 increasing.	
It	can	be	attributed	to	both	the	medical	progress	and	the	wide-
ly	understood	civilization	changes	[1].	The	US	data	demonstra-
te	that	two	thirds	of	women	at	the	above-mentioned	life	stages	
take	 various	medicines,	 often	 characterized	 by	 a	 high-toxicity	
level	[2].	Among	women	who	conceive	and	give	birth	are	those	
with	the	following	diseases:	breast,	thyroid,	cervix	and	ovarian	
cancers,	and	Hodgkin	disease	[3].	Pregnancy	also	occurs	among	
female	patients	undergoing	regular	treatment	for	such	disorders	
as	diabetes,	circulatory	problems,	epilepsy,	psychiatric	disorders,	
and	 those	 who	 are	 HIV-positive	 [4].	According	 to	 the	 recent	
estimates,	the	number	of	the	last-mentioned	females	approaches	
to	18-19	million	 in	 the	world	[5].	Also	pregnancy	itself,	 inclu-
ding	 its	 pathological	 course,	 has	 become	 an	 object	 of	medical	
intervention.	The	number	of	diagnostic	procedures	aimed	at	the	
fetus,	prognosticating	its	developmental	or	genetic	defects,	etc.,	
has	been	constantly	growing.	As	a	result,	pregnancy,	the	embryo,	
and	finally	 the	 fetus,	often	become	an	object	of	a	voluntary	or	
involuntary	intensive	therapeutic	management	involving	the	use	
of	drugs	that	are	characterized	by	high	levels	of	direct	toxic	effect	
or	 by	 long-term	effects	 that	 are	 too	 difficult	 to	 predict.	Active	
participation	 of	women	 in	 the	 job	market	 and	 their	 successful	
competition	at	work	with	men,	have	also	resulted	in	an	increased	
drug	consumption	among	them,	often	without	medical	consulta-
tion	and	solely	due	to	the	pressure	of	aggressive	advertisements	
in	 the	media.	The	drugs	whose	 consumption	by	women	 short-
ly	 before	 or/and	during	 pregnancy	has	 considerably	 increased,	
include:	 hypnotics,	 tranquillizers,	 painkillers,	 mood-improving	
drugs,	diuretics,	anti-emetics,	and	others	[6].	
In	this	situation,	the	knowledge	of	the	role	of	the	hemocho-
rial	placenta	becomes	crucial,	as	it	is	not	only	involved	in	supp-
lying	the	fetus	with	oxygen,	nutrients,	cytokines,	growth	factors,	
hormones,	and	in	eliminating	toxic	metabolites,	but	also	acting	as	
a	protective	barrier	for	endobiotics,	xenobiotics,	systems	of	pas-
sive	drug	transport,	facilitated	diffusion,	and	active	transport,	the	
last	–mentioned	one	represented,	among	others,	by	ABC	trans-
porters	with	 an	ATP-binding	 cassette.	The	knowledge	of	 these	
issues	is	indispensable	to	draw	rational	and	effective	therapeutic	
decisions	concerning	pregnancy	and,	simultaneously,	to	minimi-
ze	any	possible	hazards	to	human	health	and	fetal	development.	
The	issue	is	further	complicated	by	the	fact	that	in	the	course	of	
pregnancy	the	placenta	not	only	undergoes	significant	structural	
transformations	but	also	participates	in	the	bio-transformation	of	
xenobiotics	and	endogenous	substrates,	to	a	varying	extent	rela-
ted	 to	 the	particular	 trimester	of	gestation.	These	processes,	 in	
turn,	are	subject	to	modifications	effected	by	smoking	and	alco-
hol,	psychoactive	substances	intake	[7,	8].	
In	Poland,	approximately	40%	of	women	smoke	during	pre-
gnancy.	The	placental	transport	systems,	both	active	and	passi-
ve,	mutually	compete	for	the	substrates,	and	often	their	transport	
vector	changes.	Besides,	in	the	course	of	pregnancy,	the	expres-
sion	of	the	active	transporters	in	the	particular	cells	and	structu-
res	of	the	placenta	evolves.	Some	of	them	dominate	in	the	first	
trimester	of	gestation,	others	gradually	increase	their	activity	as	
the	organ	matures,	yet	others	are	characterized	by	a	stable	action	
throughout	the	whole	gestational	period	[9,	10].	
The	advancement	of	 the	processes	of	exchange	of	various	
substrates	is	related	to:
a.	 Increasing	 contact	 surface	 of	 the	 placental	 syncytio-
trophoblast	 with	 the	 maternal	 blood	 from	 3.4m2	 at	 28	
weeks	of	gestation	up	to	12.6m2	in	the	third	trimester.
b.	Increasing	intensity	of	blood	flow	in	the	placental	vessels	
from	50ml	per	minute	at	10	weeks	of	gestation	up	to	600	
ml	per	minute	at	the	termination	of	pregnancy.	
c.	The	 thinning	 /decreasing	diameter/μm	of	 the	barrier	 se-
parating	 the	 maternal	 blood	 from	 the	 fetal	 one	 from	
20/30μm	at	the	beginning	of	pregnancy	down	to	4μm	at	
term	pregnancy	[11].	
The	aim	of	this	article	is	to	outline	these	issues	to	obstetri-
cians,	perinatologists	and	other	specialists.
The placental structure
Human	beings	have	at	 their	disposal	 the	hemochorial	pla-
centa,	characterized	by	a	direct	contact	of	 the	developing	 fetal	
tissues	with	the	maternal	blood.	This	is	a	discoid,	invasive	pla-
centa.	It	can	be	distinguished	from	the	endotheliochorial	placen-
ta,	 found	 in	 dogs	 and	 cats,	 and	 also,	 from	 the	 epitheliochorial	
placenta,	typical	for	sheep,	swine,	or	horse.	(Table	I).	
Its	structure	is	composed	of	the	fetal	tissue	groups,	forming	
the	 chorionic	membrane	along	with	 the	villi,	 and	 the	maternal	
part,	the	so-called	decidua	/deciduous	membrane/.	Each	placen-
ta	forms	from	twenty	to	forty	well-ordered	compartments	called	
cotyledons	[11].	The	latter	function	as	an	open	vascular	system.	
Each	of	 the	cotyledons	fills	up	 the	chorionic	 tree,	which	 is	 the	
consequence	of	the	ramification	of	the	chorionic	trunks	into	the	
so-called	terminal	villi,	the	tertiary	ones.	Some	of	the	branches	
of	 the	chorionic	 trunk	 reach	 the	basal	deciduous	membrane	as	
the	 so-called	 anchoring	 villi.	Thus,	 each	 chorionic	 trunk,	with	
its	 numerous	 terminal	 villi,	 is	 separated	 from	 the	 fetal	 part	 by	
the	chorionic	membrane,	from	the	maternal	part	by	the	decidu-
ous	membrane,	and	from	the	sides,	by	the	incomplete	deciduous	
septa.	The	system	of	the	barriers	between	the	maternal	blood	and	
the	fetal	blood	is	formed	by	the	continuous	endothelium	of	the	
fetal	capillary	circulation,	the	mesenchymal	tissue	with	Hofbauer	
cells	 (forming	 the	 stroma	 of	 the	 villi),	 the	 syncytiotrophoblast	
resting	on	 the	continuous	basal	membrane,	 and	 the	underlying	
cytotrophoblast.	It	is	the	syncytiotrophoblast	which	plays	a	par-
ticularly	important	role	in	the	formation	of	the	above-mentioned	
barrier	and	also	in	the	formation	of	the	active	transporters	of	va-
rious	xeno-	and	endogenous	substrates.	In	its	free	/unbound/	sur-
face	facing	the	maternal	blood,	the	syncytiotrophoblast	is	equi-
pped	with	a	vast	system	of	micro-villi,	considerably	increasing	
the	substrate-exchange	surface.	At	the	initial	stages	of	placental	
development,	and	in	particular,	in	the	first	trimester	of	pregnan-
cy,	 the	 epithelium	 is	 stratified,	 as	 a	 rule,	 and	 the	 thickness,	 or	
diameter,	of	the	barrier	often	exceeds	20-30μm.	In	the	course	of	
pregnancy,	as	the	fetal	weight	increases,	the	placental	barrier	un-
dergoes	gradual	thinning	so	that	towards	the	final	phase	of	gesta-
tion	(at	term	pregnancy)	it	is	reduced	down	to	2-5μm	in	diameter	
[8,	11].	The	above-mentioned	reduction	in	the	barrier	thickness	is	
due	to	the	extension	of	the	chorionic	villi	capillaries,	their	shift	to	
the	vicinity	of	the	syncytiotrophoblast	basal	membrane,	atrophy	
or	considerable	reduction	of,	and	the	continuous	arrangement	of,	
the	 cytotrophoblast	 cells,	 and	 considerable	 transformations	 in	
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the	structure	of	the	polynucleous	syncytiotrophoblast	cells,	con-
sisting	in	the	formation	of	the	vasculo-epithelial	membranes	and	
the	syncytiotrophoblastic	buds.	The	above-mentioned	process	of	
placental	structure	transformation	is	accompanied	by	vast	chan-
ges	in	the	activities	of	its	drug-metabolizing	systems,	including	
the	1st	and	2nd	phase	enzymes,	as	well	as	by	the	quantitative	and	
qualitative	evolution	in	 the	particular	 transporters	[8,	11].	As	a	
result	of	the	above-signaled	transformations	within	the	placental	
structure	and	due	to	changes	in	the	activity	of	the	enzymes	me-
tabolizing	the	exo-	and	endogenous	products	as	well	as	changes	
in	the	expression	of	the	various	transporters	from	ABC	family	or	
other	transporters,	the	barrier	role	of	the	placenta	undergoes	con-
siderable	evolution	in	the	course	of	pregnancy:	from	the	preva-
lence	of	the	protective	function	in	the	initial	phase	of	pregnancy,	
i.e.	when	the	embryo	(and	then,	the	fetus),	forms	its	blastodermic	
layers,	 to	 the	 favor	of	other	 functions,	 including	 the	metabolic	
ones,	 resulting	 from	 the	 ever-increasing	 fetal	demand	 for	oxy-
gen,	nutrients,	hormones,	and	other	products	[4,	11].
Unfortunately,	lack	of	the	fetomaternal	circulation	up	to	10	
weeks	of	gestation,	i.e.	in	the	phase	of	an	intensive	organogenesis	
of	the	embryo,	does	not	completely	eliminate	the	toxic	or	emb-
ryotoxic	effects	of	xenobiotics,	which	effectively	influx	the	fetal	
cells	by	way	of	the	bodily	tissue	fluid	via	the	wide	intercellular	
spaces.						
The mechanisms of drug transportation 
in the placenta
In	addition	to	the	earlier-mentioned	active	transporters	from	
ABC	 family,	 the	 placental	 exchange	 is	 effected	 in	 other	ways	
as	well,	including	passive	transport,	facilitated	diffusion,	phago-
cytosis	 and	 pinocytosis.	The	 latter	 two	ways	 are	 of	 secondary	
clinical	 significance,	as	 they	are	hardly	effective.	For	 instance,	
glucocorticoids,	ganciclovir	and	cephalosporin	can	be	transpor-
ted	in	this	way	[11].
Passive transport
Undoubtedly,	passive	transport	appears	to	be	the	main	way	
of	substrate	exchange	in	the	placenta.	It	uses	the	differences	in	
the	concentrations	of	the	substances	transported	between	the	ma-
ternal	blood	and	the	fetal	tissues.	The	difference	in	the	concentra-
tion	gradient	of	these	substances	triggers	their	efflux.		
The	 physical	 diffusion	 does	 not	 require	 energy	 input,	 the	
process	 does	 not	 undergo	 saturation	 or	 competence	 inhibition.	
Drugs	undergoing	this	process	are	those	characterized	by	a	low	
molecular	weight,	good	 solubility	 in	 fats,	 and	 they	are	usually	
non-ionized.	 Drugs	 with	 the	 molecular	 weight	 of	 500	 daltons	
permeate	 though	 the	placenta	only	 in	part,	and	 those	weighing	
above	 1000	 daltons	 do	 this	 with	 extreme	 difficulty	 [11].	 The	
course	 and	 effectiveness	 of	 the	 passive	 diffusion	 undergo	mo-
difications	which	are	subject	to	the	conditions	developed	by	the	
placenta	itself,	by	its	structure,	and	dependent	on	the	biochemical	
and	physiological	processes	occurring	within	the	placental	area.	
The	placental	membranes	are	easily	permeable	to	drugs	soluble	
in	 lipids,	 but	 hardly	 permeable	 to	 drugs	 soluble	 in	water	 [11].	
Most	drugs,	being	weak	acids	or	alkali	at	the	physiological	pH,	
are	 found	 in	 the	 ionized	 form,	which	 inhibits	 their	passage	 to-
wards	both	the	mother	and	the	fetus.	Drugs	that	circulate	freely,	
unbound	to	blood	proteins,	permeate	through	the	placento-fetal	
barrier.	Although	many	of	these	proteins	may	temporarily	bind	
to	drugs,	 the	 leading	 role	 is	given	 to	albumins	and	α1	acidous	
glycoprotein.	Albumins	bind	to	drugs	that	are	acidous,	whereas	
α1	 glycoprotein	binds	 to	alkaline	drugs.	As	 the	gestational	age	
increases,	the	content	of	the	acidous	glycoprotein	in	the	maternal	
bloodstream	remains	on	a	stable	level,	whereas	the	albumin	con-
tent	systematically	decreases.	Conversely,	α1	glycoprotein	con-
tent	increases	from	approximately	10%	of	the	level	found	in	the	
maternal	blood	at	10	weeks	of	gestation	to	30-40%	at	term	pre-
gnancy.	Therefore,	in	consequence	of	the	above-described	evolu-
tion	in	the	concentrations	of	the	acidous	glycoprotein	in	the	fetal	
blood,	one	may	prognosticate	increased	concentration	values	of	
the	alkaline	drugs	in	the	fetal	tissues.	Furthermore,	the	affinity	of	
the	above-mentioned	proteins	to	certain	drugs	undergoes	chan-
ges.	Albumins	are	characterized,	among	others,	by	high	affinity	
to	such	drugs	as:	local	anesthetics,	phenobarbital,	phenytoin,	and	
by	lower	affinity	to	salicylates.	A	number	of	drugs	become	perio-
dically	deposited	within	the	area	of	the	placental	structures.	Such	
is	the	case	with	buprenorphin	[11].
 
   
       
Table I. Structural and functional features of selected mammalian placentas. 
©  P o l s k i e  T o w a r z y s t w o  G i n e k o l o g i c z n e 777
P R A C E  P O G L Ñ D O W E
  p o ∏ o˝ni c two 
Włoch S, et al.
Ginekol Pol. 2009, 80, 772-777 
Active transport
The	proteins	playing	a	fundamental	role	in	active	efflux	of	
xenobiotics	and	endogenous	substrates	of	the	syncytiotrophoblast	
into	 the	maternal	blood	 include	 transporters	with	 the	ATP-bin-
ding	cassette	(ABC	family).	These	proteins	are	characterized	by	
a	considerable	homology	of	the	amino-acid	sequence.	They	use	
the	energy	produced	as	a	result	of	ATP	hydrolysis	for	the	trans-
portation	 of	 many	 substrates,	 in	 defiance	 of	 the	 concentration	
gradient	[6].	The	molecules	of	the	above-mentioned	transporters	
have	12-17	transmembrane	regions.	Most	of	them	act	in	the	form	
of	monomers	as	the	so-called	“semi-transporters”,	and	some	of	
them	dimerize	e.g.	breast	cancer	resistance	protein	–BCRP	[12].	
What	seems	worth	considering,	is	the	vast	diversity	of	the	trans-
ported	substrates,	both	exo-	and	endogenous.	This	diversity	ma-
kes	the	following	question	how	these	transporters	ensure	adequa-
te	transport-specificity?	[12,	13]	relevant.	
The	effective	drug	efflux	pumps,	effluxing	drugs	 from	 the	
fetal	blood	and	from	the	syncytiotrophoblast	cells	 into	the	ma-
ternal	blood,	 include:	 immunosuppressive	drugs,	HIV	protease	
inhibitors,	 antineoplastic	 drugs,	 tranquillizers,	 anticonvulsants,	
antiparasitic	 and	 antibacterial	 drugs,	 cardiovascular	 drugs,	 and	
others	[12].	Among	the	effluxed	endogenous	substrates	are:	ste-
roid	hormones,	thyroxin,	certain	cytokines,	vitamins,	prostaglan-
dins	[12].	The	suprafamily	of	ABC	transporters	having	the	ATP-
binding	cassette	includes:	P-glycoprotein	(P-gp),	MDR	1/ABCB	
1	and	MDR	3/ABCB	4,	breast	cancer	resistance	protein	(BCRP/	
ABCG	2),	and	multidrug	resistance	proteins	(MRPs	/ABCC	1-6	
and	10-11)	[4].		
P-glycoprotein (MDR 1/ ABCC 1)
It	is	one	of	the	most	important	and	earliest-known	transpor-
ters.	This	relatively	large	protein	(170kD),	is	located	exclusive-
ly	 on	 the	 apical	 surfaces	 of	 the	microvilli,	which	 significantly	 
extend	the	substrate	area	within	the	syncytiotrophoblast	(Fig.	2).
It	transports	hydrophobic,	uncharged,	weak	alkaline	substra-
tes	whose	molecular	weight	 varies	 from	 220-1880	Da.,	 in	 the	
fetomaternal	direction	[11].	It	participates	in	the	elimination	of	
such	 toxic	 metabolites,	 forming	 within	 the	 placental	 area	 and	
other	organ	regions,	as:	unconjugated	bilirubin,	free	fatty	acids,	
neurotransmitters,	estradiol	conjugated	with	glucuronic	acid,	and	
glycocorticoids.	Drugs	that	undergo	elimination	include:	verapa-
mil,	 nifedipine,	 digoxin,	 paclitaxel,	 etoposide,	 vinblastine,	 do-
xorubicin,	methadone,	phenytoin,	simvastatin,	and	many	others.	
The	experimental	 research	on	mice	with	mdr1	knock-out	gene	
and	on	those	deprived	of	glycoprotein	(P-gp)	has	convincingly	
demonstrated	that	the	above-mentioned	transporter	has	a	signifi-
cant	fetoprotective	function,	protecting	the	fetus	against	the	toxic	
or	 teratogenic	activities	of	many	xenobiotics	and	 their	 indirect	
metabolites	[11].
In	 turn,	 the	product	of	MDR	3	 /ABCB	4	gene	 acts	 in	 the	
hepatic	cells	as	a	lipase	in	the	translocation	of	phospholipids	to	
the	bile	[14,	15].	
Structurally,	it	is	located	in	the	endoplasmic	reticulum,	i.e.	
in	the	close	vicinity	of	the	enzymes	from	the	cytochromeP450-	
dependent	monooxygenase	group,	converting	xenobiotics.	In	the	
placenta,	the	expression	of	MDR	3	has	been	demonstrated	in	the	
baso-lateral	 segments	 of	 the	 syncytiotrophoblast	 plasmalemma	
and	in	the	endothelial	cells	of	the	capillaries	of	the	villi.	Its	acti-
vity	increases	in	the	course	of	gestation	and	reaches	its	peak	in	
the	third	gestational	trimester,	which	distinguishes	it	significantly	
from	Pgp1,	which	dominates	in	the	first	trimester	[10].	
The	transport	protein	under	discussion	not	only	participates	
in	the	transport	of	phospholidylothoine	but	also	in	the	transport	
of	the	bile	acids,	digoxin,	vinblastine,	and	paclitaxel.	The	trans-
portation	role	of	the	MDR	3	protein	in	the	placenta	is	not	very	
well	documented.			
 
Figure 1. Schematic representation of bidirectional transport of drugs and their metabolites across the human placenta.
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MRP/ABCC multidrug resistance proteins
The	molecular	weight	of	these	proteins	varies	from	190-200	
kD.	They	participate	in	the	process	of	ATP-dependent	transmis-
sion	of	the	endogenous	amphiphilic	and	lipophilic	substrates	and	
xenobiotics,	conjugated	with	sulphates	or	glucuronic	acid.	These	
proteins	with	additional	250	aminoacids	in	the	molecule	are	cha-
racterized	by	a	higher	substrate	specificity	than	Pgp	in	relation	to	
many	drugs.	MPR1,	MPR4,	and	MPR5	are	widely	represented	in	
various	organs,	whereas	MPR2,	MPR3,	and	MPR6	are	usually	
located	in	the	liver,	kidneys	and	intestines	[4].	
Drugs	that	are	effluxed	from	the	fetal	blood	into	the	maternal	
blood,	or	in	the	opposite	direction,	include:	methotrexate,	etopo-
side,	vinblastine,	vincristine,	HIV-protease	inhibitors,	some	anti-
biotics	from	the	fluorochinolons	group,	ampicillin.	They	show	a	
diversified	cellular	location	in	the	placenta	and	different	expres-
sion	levels	in	the	particular	gestational	trimesters	[4].	
MPR1	expression	increases	with	maturation	of	the	placen-
ta,	 and,	 immunocytochemically,	 it	 is	 located	 in	 the	endothelial	
cells	of	the	capillaries	of	the	villi	and	at	the	base	of	the	syncytio-
trophoblast	[16].	
The	activity	of	MPR2,	in	turn,	is	restricted	solely	to	the	mic-
rovilli	of	the	syncytiotrophoblast	and	is	also	dominant	in	the	late	
gestational	phase.	As	far	as	MPR3	is	concerned,	it	shows	a	stable	
activity	level	until	the	end	of	the	third	gestational	trimester.	It	is	
found	both	 in	 the	 syncytiotrophoblast	 and	 in	 the	 endothelia	of	
the	 capillaries	 of	 the	 villi.	 Some	data	 in	 the	 literature	 seem	 to	
suggest	that	this	pump	propels	medicines	into	both	the	fetal	and	
the	maternal	organisms	[17].	
As	 regards	MPR4,	 although	 it	 shows	 transport	 activity	 in	
the	placenta	towards	many	substrates,	yet,	 there	is	no	certainty	
as	to	in	what	structures	it	is	located.	It	effluxes	zidovudine	from	
the	placenta	into	the	maternal	blood,	it	transports	several	prosta-
glandins	including	PGE1	and	PGE2,	playing	an	important	role	in	
the	regulation	of	the	vascular	bed	of	the	villi	and	in	other	mecha-
nisms	regulating	the	homeostasis	of	the	fetus	[19].	
MPR5	transports	in	the	placenta	the	cyclic	nucleotides,	par-
ticularly	Comp,	locating	itself	in	the	vesicles	and	vacuoles	that	
are	distributed	in	the	close	vicinity	of	the	basal	membrane	of	the	
syncytiotrophoblast	and	in	the	endothelia	of	the	capillaries	of	the	
villi.	Its	increased	activity	pertains	to	the	first	trimester	of	gesta-
tion,	in	which	it	regulates	the	organogenesis	and	differentiation	
of	the	fetus	by	affecting	the	Comp	level.	
As	 to	MPR7/ABCC10,	MPR8ABC11	 and	ABCC13,	 they	
are	found	in	the	placental	cells	in	low	concentrations.	Their	cel-
lular	location	has	not	been	established	yet.	They	probably	play	a	
role	in	fetal	resistance	to	some	antiviral	drugs.	They	efflux	from	
the	placenta	into	the	maternal	blood	such	substances	as:	cyclic	
nucleotides,	bile	acids,	conjugated	steroids,	eicosanoids	[19].
Breast cancer resistance protein 
(BRCP/ABCG2)
It	is	also	known	as	mitoxantrone-resistance	protein	or	ABC	
placental	 specific	 protein	 [20,	 21].	 It	 is	 characterized	 by	 high	
mRNA	and	protein	levels	throughout	the	whole	gestational	pe-
riod.	It	is	located	in	the	microvilli	of	the	syncytiotrophoblast	of	
the	villi	and	in	the	uterus	[21].	
Although	the	role	of	the	above-discussed	transporter	in	the	
placenta	has	not	been	ultimately	established,	there	are	many	ar-
guments	in	favor	of	its	status	as	an	effective	and	stable	partner	
for	the	placental	barrier,	 in	addition	to	P-gp,	 in	respect	 to	such	
substrates	as:	organic	cations,	lipophilic	conjugated	derivatives,	
and	in	particular,	antineoplastic	drugs	(topotecan,	mitoxantrone,	
quercetin,	doxorubicin,	methotrexate)	[22].	It	also	effluxes	from	
the	placenta	and	the	fetus	into	the	maternal	blood	such	substan-
ces	as	imatinib,	nitrofurantoin,	and	zidovudine.	Besides,	it	remo-
ves	the	conjugated	steroids.					
 
Figure 2. Histological  localization of drug transporters in the terminal villus of the human placenta.   
BCRP: breast cancer-resistance protein; hENT: human equilibrative nucleoside transporter; MCT: monocarboxylate transporter, MDR: multi-drug resistance,  
MRP: multi-drug resistance protein; NET; norepinephrine transporter, OAT: organic anion transporter; OCT: organic cation transporter; OCTN organic cation/carnitine transporter; 
SERT: serotonin transporter (see text for detailed information).
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Placental transporters of SLC soluble 
substrates 
Organic anion transporters (OAT/SLC22A family)
This	family	plays	a	dominant	role	in	the	elimination	through	
the	kidneys	of	a	number	of	metabolites	such	as	urates,	uremic	to-
xins,	fatty	acids,	prostaglandins,	conjugated	steroids,	neurotrans-
mitter	metabolites,	and	selected	xenobiotics	(chemotherapeutics,	
β-lactam	 antibiotics,	 and	 antiviral	 nucleoside	 analogues	 [23].	
In	 the	 placenta,	 the	 presence	 of	OAT1	 and	OAT3	 in	 the	 basal	
membrane,	on	which	the	syncytiotrophoblasts	rest,	and	OAT4	in	
the	syncytiotrophoblast	cells,	has	been	confirmed.	The	first	two	
organic	anion	 transporters	are	connected	with	 the	efflux	of	xe-
nobiotics	from	the	fetal	circulation,	whereas	the	third	mentioned	
one	effluxes	the	conjugated	steroids	into	the	maternal	circulation	
[4,	25].
Polypeptide organic anion transporters OATP/SLCO
In	the	placenta,	the	expressions	of	OATP	A,	OATP	B,	OATP	
8,	OATP	D,	and	OATP	E	have	been	confirmed	[25,	26,	27,	28].	
OATP	B	is	located	in	the	basolateral	segment,	whereas	OATP	A,	
at	the	apex	of	the	microvilli	of	the	syncytiotrophoblast	covering	
the	villi.	
Organic cation transporters SLC22
OCTN1/SLC22A4	and	OCTN2/SLC22A5	are	located	in	the	
microvilli	of	 the	syncytiotrophoblast.	They	demonstrate	a	high	
level	of	activity	 in	 the	 third	gestational	 trimester	with	 its	peak	
just	before	parturition.	OCTN1	transports	bile	salts	and	antiviral	
drugs	in	the	feto-maternal	direction,	whereas	OCTN	2	transports	
carnitine	in	the	opposite	direction	[29].
Monoamine transporters SLC6A and SLC22A
SERT/SLC6A4	 serotonin	 transporter	 and	 NET/SLC6A2	
dopamine-norepinephrine	 transporter	 are	 located	 in	 the	 apical	
surface	of	the	microvilli	of	the	syncytiotrophoblast.	They	trans-
port	to	the	fetus,	respectively,	serotonin	and	dopamine,	and	also	
amphetamine.	The	effectiveness	of	this	process	depends	on	the	
established	sodium	and	chloride	anion	gradient.	
The	OCT3/SLC22A3	transporter,	in	turn,	whose	activity	is	
determined	by	the	current	membrane	potential,	transports	in	the	
fetomaternal	 direction,	 via	 the	 placenta,	 not	 only	monoamines	
but	 also	 amphetamine,	 imipramine,	 clonidine,	 and	 cimetidine.	
Immunocytochemically,	 it	 is	 located	 in	 the	syncytiotrophoblast	
plasmalemma,	adjacent	to	the	basal	membrane.	
Carboxylate transporters SLC16
The	proton	gradient,	 in	the	case	of	monocarboxylates,	and	
the	sodium	ion	gradient,	in	the	case	of	dicarboxylates,	are	used	
as	the	driving	force	for	the	efflux	through	the	placental	barrier.	
NCT1	is	located	in	the	basilar	membrane,	whereas	NCT4	on	the	
apical	surface	of	the	syncytiotrophoblast.	NCT4	removes	lactates	
from	the	fetus	and	the	placenta	[30].	
It	 also	 transports	 acetylsalicylic	 acid	 and	 organic	 acids	 in	
accordance	with	the	concentration	gradient	in	the	materno-fetal	
compartment.	
Nucleoside transporters SLC29A
hENT1/SLC29A1	 and	 hENT2/SLC29A2	 are	 located	 in	
the	syncytiotrophoblast	cells,	 in	 the	microvilli	and	 in	 the	basal	
cell	membrane,	 respectively.	 hENT3,	 in	 turn,	 shows	 a	 structu-
ral	connection	with	the	intracellular	membranes	of	the	syncytio-
trophoblast.	They	are	probably	lysosomes	[31,	32].	The	distribu-
tion	of	hENT2	is	not	yet	known.
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